logo-loader
viewVolitionRx

VolitionRx records first revenues from research kits and strengthens balance sheet in third quarter

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds talks Proactive London's Andrew Scott through the firm's third quarter update.

He says excellent progress has been made on platform development - Nu.Q Capture, Nu.Q Vet and its colorectal cancer and lung cancer trials.

Volition also reported first revenues in the period from sales of Research Use Only kits and the provision of contract research services.

Quick facts: VolitionRx

Price: 3.2 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $131.85 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO highlights 'very strong assay and platform development progress'

VolitionRx Limited's (NYSEAMERICAN:VNRX) president and CEO Cameron Reynolds recaps on what he describes as a year of 'very strong progress' in assay and platform development with its Nu.Q Capture program and epigenetic toolkit Nu.Q Vet. Heading into 2020, Reynolds says the company's well...

on 21/2/20

2 min read